[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP

Sarah Coakeley, Sang Soo Cho, Yuko Koshimori, Pablo Rusjan, Christine Ghadery, Jinhee Kim, Anthony E. Lang, Sylvain Houle, Antonio P. Strafella

Research output: Contribution to journalArticle

Abstract

This study investigated binding of [18F]AV-1451 to neuromelanin in the substantia nigra of patients with Parkinson’s disease (PD) and progressive supranuclear palsy (PSP). [18F]AV-1451 is a positron emission tomography radiotracer designed to bind pathological tau. A post-mortem study using [18F]AV-1451 discovered off-target binding properties to neuromelanin in the substantia nigra. A subsequent clinical study reported a 30% decrease in [18F]AV-1451 binding in the midbrain of PD patients. A total of 12 patients and 10 healthy age-matched controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio (SUVR) from 60 to 90 min post-injection was calculated for the substantia nigra, using the cerebellar cortex as the reference region. The substantia nigra was delineated using automated region of interest software. An independent samples ANOVA and LSD post hoc testing were used to test for differences in [18F]AV-1451 SUVR between groups. Substantia nigra SUVR from 60 to 90 min was significantly greater in HC compared to both PSP and PD groups. Although the PD group had the lowest SUVR, there was no significant difference in substantia nigra uptake between PD and PSP. [18F]AV-1451 may be the first PET radiotracer capable of imaging neurodegeneration of the substantia nigra in parkinsonisms. Further testing must be done in PD and atypical parkinsonian disorders to support this off-target use of [18F]AV-1451.

Original languageEnglish (US)
Pages (from-to)589-595
Number of pages7
JournalBrain Structure and Function
Volume223
Issue number2
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Progressive Supranuclear Palsy
Substantia Nigra
Parkinson Disease
Positron-Emission Tomography
Lysergic Acid Diethylamide
Cerebellar Cortex
Parkinsonian Disorders
Mesencephalon
neuromelanin
Analysis of Variance
Software
Injections

Keywords

  • Neuromelanin
  • Parkinson’s disease
  • Positron emission tomography
  • Progressive supranuclear palsy
  • [F]AV-1451

ASJC Scopus subject areas

  • Anatomy
  • Neuroscience(all)
  • Histology

Cite this

Coakeley, S., Cho, S. S., Koshimori, Y., Rusjan, P., Ghadery, C., Kim, J., ... Strafella, A. P. (2018). [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Structure and Function, 223(2), 589-595. https://doi.org/10.1007/s00429-017-1507-y

[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. / Coakeley, Sarah; Cho, Sang Soo; Koshimori, Yuko; Rusjan, Pablo; Ghadery, Christine; Kim, Jinhee; Lang, Anthony E.; Houle, Sylvain; Strafella, Antonio P.

In: Brain Structure and Function, Vol. 223, No. 2, 01.03.2018, p. 589-595.

Research output: Contribution to journalArticle

Coakeley, S, Cho, SS, Koshimori, Y, Rusjan, P, Ghadery, C, Kim, J, Lang, AE, Houle, S & Strafella, AP 2018, '[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP', Brain Structure and Function, vol. 223, no. 2, pp. 589-595. https://doi.org/10.1007/s00429-017-1507-y
Coakeley, Sarah ; Cho, Sang Soo ; Koshimori, Yuko ; Rusjan, Pablo ; Ghadery, Christine ; Kim, Jinhee ; Lang, Anthony E. ; Houle, Sylvain ; Strafella, Antonio P. / [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. In: Brain Structure and Function. 2018 ; Vol. 223, No. 2. pp. 589-595.
@article{ca999ad1fdb24b96817ec4113f39a00b,
title = "[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP",
abstract = "This study investigated binding of [18F]AV-1451 to neuromelanin in the substantia nigra of patients with Parkinson’s disease (PD) and progressive supranuclear palsy (PSP). [18F]AV-1451 is a positron emission tomography radiotracer designed to bind pathological tau. A post-mortem study using [18F]AV-1451 discovered off-target binding properties to neuromelanin in the substantia nigra. A subsequent clinical study reported a 30{\%} decrease in [18F]AV-1451 binding in the midbrain of PD patients. A total of 12 patients and 10 healthy age-matched controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio (SUVR) from 60 to 90 min post-injection was calculated for the substantia nigra, using the cerebellar cortex as the reference region. The substantia nigra was delineated using automated region of interest software. An independent samples ANOVA and LSD post hoc testing were used to test for differences in [18F]AV-1451 SUVR between groups. Substantia nigra SUVR from 60 to 90 min was significantly greater in HC compared to both PSP and PD groups. Although the PD group had the lowest SUVR, there was no significant difference in substantia nigra uptake between PD and PSP. [18F]AV-1451 may be the first PET radiotracer capable of imaging neurodegeneration of the substantia nigra in parkinsonisms. Further testing must be done in PD and atypical parkinsonian disorders to support this off-target use of [18F]AV-1451.",
keywords = "Neuromelanin, Parkinson’s disease, Positron emission tomography, Progressive supranuclear palsy, [F]AV-1451",
author = "Sarah Coakeley and Cho, {Sang Soo} and Yuko Koshimori and Pablo Rusjan and Christine Ghadery and Jinhee Kim and Lang, {Anthony E.} and Sylvain Houle and Strafella, {Antonio P.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s00429-017-1507-y",
language = "English (US)",
volume = "223",
pages = "589--595",
journal = "Brain Structure and Function",
issn = "1863-2653",
number = "2",

}

TY - JOUR

T1 - [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP

AU - Coakeley, Sarah

AU - Cho, Sang Soo

AU - Koshimori, Yuko

AU - Rusjan, Pablo

AU - Ghadery, Christine

AU - Kim, Jinhee

AU - Lang, Anthony E.

AU - Houle, Sylvain

AU - Strafella, Antonio P.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - This study investigated binding of [18F]AV-1451 to neuromelanin in the substantia nigra of patients with Parkinson’s disease (PD) and progressive supranuclear palsy (PSP). [18F]AV-1451 is a positron emission tomography radiotracer designed to bind pathological tau. A post-mortem study using [18F]AV-1451 discovered off-target binding properties to neuromelanin in the substantia nigra. A subsequent clinical study reported a 30% decrease in [18F]AV-1451 binding in the midbrain of PD patients. A total of 12 patients and 10 healthy age-matched controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio (SUVR) from 60 to 90 min post-injection was calculated for the substantia nigra, using the cerebellar cortex as the reference region. The substantia nigra was delineated using automated region of interest software. An independent samples ANOVA and LSD post hoc testing were used to test for differences in [18F]AV-1451 SUVR between groups. Substantia nigra SUVR from 60 to 90 min was significantly greater in HC compared to both PSP and PD groups. Although the PD group had the lowest SUVR, there was no significant difference in substantia nigra uptake between PD and PSP. [18F]AV-1451 may be the first PET radiotracer capable of imaging neurodegeneration of the substantia nigra in parkinsonisms. Further testing must be done in PD and atypical parkinsonian disorders to support this off-target use of [18F]AV-1451.

AB - This study investigated binding of [18F]AV-1451 to neuromelanin in the substantia nigra of patients with Parkinson’s disease (PD) and progressive supranuclear palsy (PSP). [18F]AV-1451 is a positron emission tomography radiotracer designed to bind pathological tau. A post-mortem study using [18F]AV-1451 discovered off-target binding properties to neuromelanin in the substantia nigra. A subsequent clinical study reported a 30% decrease in [18F]AV-1451 binding in the midbrain of PD patients. A total of 12 patients and 10 healthy age-matched controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio (SUVR) from 60 to 90 min post-injection was calculated for the substantia nigra, using the cerebellar cortex as the reference region. The substantia nigra was delineated using automated region of interest software. An independent samples ANOVA and LSD post hoc testing were used to test for differences in [18F]AV-1451 SUVR between groups. Substantia nigra SUVR from 60 to 90 min was significantly greater in HC compared to both PSP and PD groups. Although the PD group had the lowest SUVR, there was no significant difference in substantia nigra uptake between PD and PSP. [18F]AV-1451 may be the first PET radiotracer capable of imaging neurodegeneration of the substantia nigra in parkinsonisms. Further testing must be done in PD and atypical parkinsonian disorders to support this off-target use of [18F]AV-1451.

KW - Neuromelanin

KW - Parkinson’s disease

KW - Positron emission tomography

KW - Progressive supranuclear palsy

KW - [F]AV-1451

UR - http://www.scopus.com/inward/record.url?scp=85028993833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028993833&partnerID=8YFLogxK

U2 - 10.1007/s00429-017-1507-y

DO - 10.1007/s00429-017-1507-y

M3 - Article

C2 - 28884232

AN - SCOPUS:85028993833

VL - 223

SP - 589

EP - 595

JO - Brain Structure and Function

JF - Brain Structure and Function

SN - 1863-2653

IS - 2

ER -